---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023489"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:58:05.559601+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q2 net loss narrows to $4.33M; LP-184 Phase 1a complete, complete responses in two trials

## Summary
- Q2 2025 net loss $4.33M ($0.40/share) vs $4.96M ($0.46) a year ago; cash $15.9M as of June 30, 2025.
- LP-184 Phase 1a enrollment complete (65 patients); MTD and RP2D established; advancing to Phase 1b/2 in TNBC and bladder cancer.
- LP-300 HARMONIC trial shows complete response in a 70-year-old NSCLC patient who failed three prior therapies.
- LP-284 achieves complete metabolic response in heavily pretreated DLBCL patient after two cycles.
- Cash runway extends at least into June 2026; no quarterly earnings call planned.

## SEC filing metadata
- accession: 0001641172-25-023489
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000164117225023489/0001641172-25-023489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000164117225023489/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023489
- JSON: https://secwatch.observer/filing/0001641172-25-023489.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023489.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.